Skip to main content

Bender Jeremy's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 21, 2025

Accession no.
0001415889-25-005154
Filed
Feb 21, 2025
Trade date
Feb 15-18, 2025
Filing delay
6 daysLate
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $144.1K. It was filed 6 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bender JeremyCIK 0001863107Director, Officer (CHIEF EXECUTIVE OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2025Common StockMOption exerciseAcquired+3,562––111,939Direct
Feb 15, 2025Common StockMOption exerciseAcquired+4,750––116,689Direct
Feb 15, 2025Common StockMOption exerciseAcquired+11,687––128,376Direct
Feb 15, 2025Common StockMOption exerciseAcquired+11,687––140,063Direct
Feb 18, 2025Common StockSSaleDisposed−12,048$11.96−$144,094.08128,015Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2025Common StockMOption exerciseDisposed−3,562$0.00$010,694Direct
Feb 15, 2025Common StockMOption exerciseDisposed−4,750$0.00$033,250Direct
Feb 15, 2025Common StockMOption exerciseDisposed−11,687$0.00$0128,565Direct
Feb 15, 2025Common StockMOption exerciseDisposed−11,687$0.00$0175,313Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)